HYPOTHESIS: We hypothesize that the severity of hearing loss (HL) associated with sporadic vestibular schwannomas (VS) is correlated with tumor secretion of proteins with ototoxic or otoprotective potential. BACKGROUND: Because the recognition that HL associated with VS is not solely due to compression of the auditory nerve, elucidating the mechanism by which VS cause HL has been an important task. We previously showed that VS stratified by hearing have differential gene expression. We now focus on identifying differentially expressed proteins in tumor secretions. METHODS: Fresh surgical specimens of VS were incubated in sterile PBS at 37°C to collect secretions. The specimens were divided into a group associated with good hearing (GH, word recognition ≥ 70% and pure-tone average ≤ 30 dB, n = 11) or poor hearing (PH, n = 10). The groups were compared using a customized cytokine array. Statistically significant results were verified with an enzyme-linked immunosorbent assay on a different set of secretions (n = 8 for GH and n = 10 for PH group). RESULTS: Of the 37 molecules we studied, 9 were significantly expressed in secretions from VS compared with secretions from control nerves. Secretion of fibroblast growth factor 2 (FGF2) was 3.5-fold higher in VS associated with GH versus PH based on cytokine array analysis (p = 0.02), which was validated with enzyme-linked immunosorbent assay. CONCLUSION: This study highlights FGF2, a mitogen known to protect the auditory nerve, as a potential tumor-secreted mediator of hearing protection in VS. If FGF2's significant role in hearing protection in patients with VS is validated, then FGF2 could be used as a biomarker for HL in VS, and therapeutic targeting of the FGF2 signaling pathway may reduce HL due to VS.
HYPOTHESIS: We hypothesize that the severity of hearing loss (HL) associated with sporadic vestibular schwannomas (VS) is correlated with tumor secretion of proteins with ototoxic or otoprotective potential. BACKGROUND: Because the recognition that HL associated with VS is not solely due to compression of the auditory nerve, elucidating the mechanism by which VS cause HL has been an important task. We previously showed that VS stratified by hearing have differential gene expression. We now focus on identifying differentially expressed proteins in tumor secretions. METHODS: Fresh surgical specimens of VS were incubated in sterile PBS at 37°C to collect secretions. The specimens were divided into a group associated with good hearing (GH, word recognition ≥ 70% and pure-tone average ≤ 30 dB, n = 11) or poor hearing (PH, n = 10). The groups were compared using a customized cytokine array. Statistically significant results were verified with an enzyme-linked immunosorbent assay on a different set of secretions (n = 8 for GH and n = 10 for PH group). RESULTS: Of the 37 molecules we studied, 9 were significantly expressed in secretions from VS compared with secretions from control nerves. Secretion of fibroblast growth factor 2 (FGF2) was 3.5-fold higher in VS associated with GH versus PH based on cytokine array analysis (p = 0.02), which was validated with enzyme-linked immunosorbent assay. CONCLUSION: This study highlights FGF2, a mitogen known to protect the auditory nerve, as a potential tumor-secreted mediator of hearing protection in VS. If FGF2's significant role in hearing protection in patients with VS is validated, then FGF2 could be used as a biomarker for HL in VS, and therapeutic targeting of the FGF2 signaling pathway may reduce HL due to VS.
Authors: Ted A Meyer; Paul A Canty; Eric P Wilkinson; Marlan R Hansen; Jay T Rubinstein; Bruce J Gantz Journal: Otol Neurotol Date: 2006-04 Impact factor: 2.311
Authors: C O Hanemann; B Bartelt-Kirbach; R Diebold; K Kämpchen; S Langmesser; T Utermark Journal: Neuropathol Appl Neurobiol Date: 2006-12 Impact factor: 8.090
Authors: H J Ankersmit; K Hoetzenecker; W Dietl; A Soleiman; R Horvat; M Wolfsberger; C Gerner; S Hacker; M Mildner; B Moser; M Lichtenauer; B K Podesser Journal: Eur J Clin Invest Date: 2009-04-16 Impact factor: 4.686
Authors: Konstantina M Stankovic; Maciej M Mrugala; Robert L Martuza; Michael Silver; Rebecca A Betensky; Joseph B Nadol; Anat O Stemmer-Rachamimov Journal: Otol Neurotol Date: 2009-08 Impact factor: 2.311
Authors: Shalina S Ousman; Beren H Tomooka; Johannes M van Noort; Eric F Wawrousek; Kevin C O'Connor; David A Hafler; Raymond A Sobel; William H Robinson; Lawrence Steinman Journal: Nature Date: 2007-06-13 Impact factor: 49.962
Authors: Lukas D Landegger; Jessica E Sagers; Sonam Dilwali; Takeshi Fujita; Mehmet I Sahin; Konstantina M Stankovic Journal: J Vis Exp Date: 2017-06-20 Impact factor: 1.355
Authors: Vitor Y R Soares; Nadia A Atai; Takeshi Fujita; Sonam Dilwali; Sarada Sivaraman; Lukas D Landegger; Fred H Hochberg; Carlos A P C Oliveira; Fayez Bahmad; Xandra O Breakefield; Konstantina M Stankovic Journal: Neuro Oncol Date: 2016-05-18 Impact factor: 12.300
Authors: Sonam Dilwali; Pratik B Patel; Daniel S Roberts; Gina M Basinsky; Gordon J Harris; Kevin S Emerick; Konstantina M Stankovic Journal: Hear Res Date: 2014-06-06 Impact factor: 3.208
Authors: Sonam Dilwali; Lukas D Landegger; Vitor Y R Soares; Daniel G Deschler; Konstantina M Stankovic Journal: Sci Rep Date: 2015-12-22 Impact factor: 4.379
Authors: Eric Nisenbaum; Carly Misztal; Mikhaylo Szczupak; Torin Thielhelm; Stefanie Peña; Christine Mei; Stefania Goncalves; Olena Bracho; Ruixuan Ma; Michael E Ivan; Jacques Morcos; Fred Telischi; Xue-Zhong Liu; Cristina Fernandez-Valle; Christine T Dinh Journal: OTO Open Date: 2021-11-23